XML 86 R38.htm IDEA: XBRL DOCUMENT v3.25.1
ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)
$ / shares in Units, $ in Thousands, shares in Millions
12 Months Ended
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
segment
shares
Dec. 31, 2023
USD ($)
$ / shares
shares
Apr. 30, 2025
USD ($)
Apr. 05, 2018
USD ($)
Change in Accounting Estimate [Line Items]          
Cash and cash equivalents   $ 41,918 $ 45,204    
Proceeds from at-the-market offering, net of offering expenses   7,132 15,106    
Accounts receivable   526 $ 923    
Letter of credit   $ 1,500      
Stock options, RSUs outstanding and ESPP shares reserved (in shares) | shares   50.5 21.3    
Number of operating segments | segment   1      
Forecast          
Change in Accounting Estimate [Line Items]          
Proceeds from at-the-market offering, net of offering expenses $ 10,100        
Kite Pharma, Inc.          
Change in Accounting Estimate [Line Items]          
Increase (decrease) in revenue     $ 13,900    
Increase (decrease) in net loss     $ (13,900)    
Increase (decrease) in basic net loss per share | $ / shares     $ (0.08)    
Increase (decrease) in diluted net loss per share | $ / shares     $ (0.08)    
Kite Pharma, Inc. | License          
Change in Accounting Estimate [Line Items]          
Contract with customer liability         $ 150,000
Eli Lilly | License | Forecast          
Change in Accounting Estimate [Line Items]          
Contract with customer liability       $ 5,000  
Minimum          
Change in Accounting Estimate [Line Items]          
Estimated useful lives of related assets   3 years      
Maximum          
Change in Accounting Estimate [Line Items]          
Estimated useful lives of related assets   5 years